...
首页> 外文期刊>Stem Cell Research & Therapy >Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases
【24h】

Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases

机译:利用脂肪源性干细胞的沉淀治疗缺血性心脏病

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Adipose-derived stem cells (ASCs) are promising therapeutic cells for ischemic heart diseases, due to the ease and efficiency of acquisition, the potential of myocardial lineage differentiation, and the paracrine effects. Recently, many researchers have claimed that the ASC-based myocardial repair is mainly attributed to its paracrine effects, including the anti-apoptosis, pro-angiogenesis, anti-inflammation effects, and the inhibition of fibrosis, rather than the direct differentiation into cardiovascular lineage cells. However, the usage of ASCs comes with the problems of low cardiac retention and survival after transplantation, like other stem cells, which compromises the effectiveness of the therapy. To overcome these drawbacks, researchers have proposed various strategies for improving survival rate and ensuring sustained paracrine secretion. They also investigated the safety and efficacy of phase I and II clinical trials of ASC-based therapy for cardiovascular diseases. In this review, we will discuss the characterization and paracrine effects of ASCs on myocardial repair, followed by the strategies for stimulating the paracrine secretion of ASCs, and finally their clinical usage.
机译:由于采集的缓解和效率,心肌谱系分化和旁静脉效果,脂肪衍生的干细胞(ASCS)是对缺血性心脏病的治疗细胞。最近,许多研究人员已声称,基于ASC的心肌修复主要归因于其旁静脉作用,包括抗凋亡,促血管生成,抗炎作用以及纤维化的抑制,而不是直接分化为心血管谱系细胞。然而,随着其他干细胞的移植后,ASC的使用情况涉及低心脏保留和存活的问题,这种干细胞损害了治疗的有效性。为了克服这些缺点,研究人员提出了改善生存率和确保持续的旁静脉分泌的各种策略。他们还调查了IS和II期临床试验对心血管疾病的临床试验的安全性和有效性。在本综述中,我们将讨论ASCS对心肌修复的表征和旁静脉效应,其次是刺激ASC的旁静脉分泌的策略,最后是它们的临床使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号